ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

Globally acclaimed authority on aging to further research on the potential benefits of nicotinamide riboside (NR) and age-related conditions.

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications. For the past 30 years, Dr. Bohr served as Chief of the Laboratory of Molecular Genetics at the National Institute on Aging, which is part of the National Institute of Health (NIH).

In 2014, Dr. Bohr initiated research through the industry-leading ChromaDex External Research Program (CERP™) which resulted in 11 peer-reviewed publications evaluating Niagen^®, ChromaDex’s patented nicotinamide riboside chloride (NR) ingredient. His research has been conducted in models of Alzheimer’s disease, age-related hearing loss and other conditions resulting from age-related decline. Dr. Bohr’s 2014 publication evaluating NR in a model of mitochondrial dysfunction resulting from xeroderma pigmentosum group A (XPA), a nucleotide excision DNA repair disorder with severe neurodegeneration common in ataxia-telangiectasia and Cockayne syndrome, was the first peer-reviewed publication resulting from CERP™. In the study, NR supplementation attenuated the NAD+ deficit observed in XPA cells (Cell, 2014).

“It is an honor to welcome one of the world’s most respected scientists in the field of aging to our distinguished board of scientific advisors,” said Rob Fried, CEO of ChromaDex. “Dr. Bohr’s expertise in neurodegenerative disease and in aging will help advance our understanding of this very special molecule, nicotinamide riboside, and how it improves human health.”

Dr. Bohr earned his M.D., Ph.D. and D.Sc. degrees at the University of Copenhagen, Denmark. After training in neurology and infectious diseases at the University Hospital in Copenhagen, Dr. Bohr undertook postdoctoral studies in Biochemistry in the laboratory of Dr. Hans Klenow at the University of Copenhagen, where he first became interested in nucleic acid metabolism. He developed this interest further in the laboratory of Dr. Philip Hanawalt at Stanford University where he held a Visiting Scholar position. Throughout his career, Dr. Bohr has made significant contributions and advanced understanding of DNA repair pathways, mechanisms and cellular response to oxidative DNA damage and oxidative stress.

“It’s a pleasure to join the ChromaDex SAB,” commented Dr. Bohr. “Many years of research has convinced me that NR supplementation has important benefits for many aspects of aging, and I look forward to working with ChromaDex to identify new opportunities to further this research.”

In his recent studies, Dr. Bohr has made seminal findings about the relationships between DNA damage, DNA repair capacity and age-associated neurodegeneration. Additionally, he has proposed important models describing the transfer of signals between the nuclear and mitochondrial genomes, and showcased the importance of energy homeostasis/imbalance and mitochondrial dysfunction in aging-related neurodegenerative disease. Although retiring from the National Institutes of Health, Dr. Bohr will maintain a research lab at the University of Copenhagen where he will continue to study the benefits of NR.

“Dr. Will Bohr is one of the most insightful and rigorous people in the molecular biology of aging,” said Dr. Charles Brenner, chair of the ChromaDex SAB, discoverer of the vitamin activity of NR and Alfred E Mann Family Foundation Chair of Diabetes and Cancer Metabolism at City of Hope. “I’m thrilled that we have his support at ChromaDex to expand the evidence basis and the use cases for nicotinamide riboside in human health.”

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen^®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether the full potential of how NAD+ and NR can improve human health will be further uncovered. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.